Bicara Therapeutics (BCAX) Enterprise Value (2023 - 2026)
Bicara Therapeutics (BCAX) posted quarterly Enterprise Value of -$539.8 million for Q1 2026, down 16.8% year-over-year from -$648.8 million in Q1 2025, and down 30.12% quarter-over-quarter from -$414.8 million in Q4 2025.
Bicara Therapeutics (BCAX) Enterprise Value (2023 - 2026) Analysis & Trends
Bicara Therapeutics' Enterprise Value history runs 4 years deep, the most recent figure standing at -$539.8 million for Q1 2026.
- In Q1 2026, Enterprise Value fell 16.8% year-over-year to -$539.8 million; the TTM figure through Mar 2026 stood at -$539.8 million (down 16.8% YoY), while the FY2025 annual figure was -$414.8 million, up 15.3% from the prior year.
- Enterprise Value for Q1 2026 stood at -$539.8 million, down from -$414.8 million in the prior quarter.
- The five-year high for Enterprise Value was -$230.4 million in Q4 2023, with the low at -$539.8 million in Q1 2026.
- The 4-year median for Enterprise Value is -$449.4 million (2025), against an average of -$423.0 million.
- The sharpest annual moves came in 2024 and 2025: Enterprise Value plunged 112.51% in 2024, then soared 44.28% in 2025.
- Bicara Therapeutics' Enterprise Value stood at -$230.4 million in 2023, then tumbled by 112.51% to -$489.7 million in 2024, then rose by 15.3% to -$414.8 million in 2025, then tumbled by 30.12% to -$539.8 million in 2026.
- Business Quant data shows BCAX's Enterprise Value at -$539.8 million in Q1 2026, -$414.8 million in Q4 2025, and -$290.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | -7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -7.99 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | -5.18 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -3.94 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | -5.10 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -8.46 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 2.12 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -3.31 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -1.16 Bn |
| 10 | Bicara Therapeutics | 1.60 Bn | 1.60 Bn | - | -497.26 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -497.26 Mn |
| Mar 31, 2026 | -539.75 Mn |
| Dec 31, 2025 | -414.80 Mn |
| Sep 30, 2025 | -290.17 Mn |
| Jun 30, 2025 | -436.60 Mn |
| Mar 31, 2025 | -462.10 Mn |
| Dec 31, 2024 | -489.71 Mn |
| Sep 30, 2024 | -520.80 Mn |
| Dec 31, 2023 | -230.44 Mn |